Open AccessA well‐tolerated new amino acid–based formula for cow's milk allergy
Author(s) -
Fierro Vincenzo,
Valluzzi Rocco L.,
Banzato Claudia,
Plaza Ma A.,
Bosque Montserrat,
Íbero Marcel,
Echeverría Luis A. Z.,
Mennini Maurizio,
Dahdah Lamia,
Castellar Roser,
Tort Gloria,
Jiménez Jesus
Publication year - 2020
Publication title -
immunity, inflammation and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 18
ISSN - 2050-4527
DOI - 10.1002/iid3.286
Subject(s) - tolerability , medicine , infant formula , cow's milk allergy , milk allergy , pediatrics , allergy , placebo , confidence interval , anthropometry , food allergy , adverse effect , immunology , alternative medicine , pathology
Abstract Objectives Infants with cow's milk allergy (CMA) are in need of a substitute formula up to 2 years. The are three requisites for a substitute of milk in CMA: tolerability, nutritional adequacy, and cost‐effectiveness. We evaluate here the tolerability of a new amino acid–based infant formula for the management of CMA. Methods In a phase III/IV prospective, multicentre, open‐label, international study, infants and children with immunoglobulin E‐mediated CMA were exposed to a diagnostic double‐blinded, placebo‐controlled food challenge with a new amino acid formula by Blemil Plus Elemental using Neocate as the placebo. If tolerant to it, the study formula was integrated into the patients’ usual daily diet for 7 days. Efficacy on day 7 was assessed in terms of symptoms associated with CMA, amount of formula consumed, nutritional and energy intake, and anthropometric data. Results Thirty children (17 M and 13 F; median age, 1.58; range, 0.08‐12.83 years) completed the open challenge and were able to consume the study formula for at least 7 days. No signs or symptoms of allergic reactions were recorded among children assuming either the test or the control formula, with a lower 95% one‐sided confidence interval for the proportion of subjects who did not experience allergic reactions above 90%. Sixteen patient under the age of two continued with the optional extension phase. Conclusions The study formula meets the American Academy of Pediatric criteria for hypoallergenicity and is well tolerated in short‐term use. During optional phase, growth of the patients was not hindered by the study formula.